NEW YORK (GenomeWeb News) – Foundation Medicine reported after the close of the market Wednesday that its first quarter revenues rose 121 percent from the first quarter of 2013 and 19 percent sequentially, driven by sales of its FoundationOne and FoundationOne Heme cancer tests.

The Cambridge, Mass.-based cancer genomic analysis firm reported total revenues of $11.5 million for the three months ended March 31, up from $5.2 million in Q1 2013 and $9.7 million in Q4 2013. It beat the consensus Wall Street estimate of $11.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.